PTOISBIBB (08-03)
Approved for use through 07/31/2006 (108 068-03)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
ond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to resp

	Application Number			
NEODMATION DIGGI COURT	Filing Date		2006-07-06	
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Chris		stopher M. Schnabel	
Not for submission under 37 CFR 1.99)	Art Unit			
,	Examiner Name			
	Attorney Docket Number	er	FIS920030250US1	

				U.S.	PATENTS	Remove
Examiner Initial*	r Cite No Patent Number		Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear
	1	3724068		1973-04-03	Gailt	
	2	4342090		1982-07-27	Caccoma et al.	
	3	4908092		1990-03-13	Kolbuchi	
	4	5822847		1998-10-20	Arakawa et al.	
	5	5994159		1999-11-30	Aksyuk et al.	
	6	5955801		1999-09-21	Romero et al.	
	7	6740920		2004-05-25	Chidambarrao et al.	
If you wis	h to ac	dd additional U.S. Pate	nt citatio	n information p	lease click the Add button.	Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove

### Application Number Filing Date 2006-07-06 INFORMATION DISCLOSURE First Named Inventor Christopher M. Schnabel STATEMENT BY APPLICANT Art I Init ( Not for submission under 37 CFR 1.99) Examiner Name Attorney Docket Number FIS920030250US1

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ition	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Releva Figures Appear			
	1										
If you wish	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	please click the Ad	d butto	n. Add		
				FOREIG	3N PAT	TENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Countr Code <sup>2</sup>		Kind Code4	Publication Date Name of Patente Applicant of cited Document		e or	where Rel	or Relevant	TS
	1										
If you wish	h to a	dd additional Foreign Pa	atent Do	cument	citation	information pl	lease click the Add	button	Add		
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	or Cite No Dictor, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), published.								Τs		
	1										

EYAMINED SIGNATURE \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

If you wish to add additional non-patent literature document citation information please click the Add button Add

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST 3) 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

Examiner Signature

# Application Number Fing Date 2006-07-06 First Number (Not for submission under 37 CFR 1.99) Application Number 2006-07-06 First Number (Not for submission under 37 CFR 1.99) At Unit Examiner Name Attorney Docket Number | FISSO0000250US1

## CERTIFICATION STATEMENT

Diagra can	37	CER 1	97	and	1 98 to	make the	annronniato	selection(s):

information disclosure statement. See 37 CFR 1.97(e)(1).

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the

# OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no term of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/3/(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/H. Daniel Schnurmann/	Date (YYYY-MM-DD)	2006-07-06
Name/Print	H. Daniel Schnurmann	Registration Number	35791

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GA 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via yet of sciences, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via self or in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.